| Title: | Validating externally derived omics profiles of diabetes using UK Biobank |
| Lead Institution: | University of Leeds |
| Principal investigator: |
Application 105351
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Diabetes mellitus (DM) is a disease where blood sugar levels become too high due to the body not making enough insulin or not responding properly to insulin. Currently over 4 million people in the UK have DM, with this number expected to rise in future. It can lead to a wide range of complications including blindness, kidney failure and circulatory problems like stroke and heart attack; these reduce quality of life and are linked with increased risk of death. Modern laboratory techniques, referred to collectively as 'omics, allow us to collect a snapshot of what is going on in a blood or tissue sample by measuring the levels of proteins or other molecules that our cells use to function. This information gives a complete picture of what happens in people with diabetes, which can be very useful in finding new treatment targets and diagnostic tests, but it generates very large lists of molecular differences that need to be confirmed and explored in follow-on studies. Using blood and tissue samples collected from people with and without diabetes in our own research and other published research, we are creating lists of molecular differences in people with diabetes identified by these 'omic technologies. We plan to use UK Biobank to perform follow-on studies to check whether we find similar differences in people with diabetes. For molecules that we confirm, we will then use UK Biobank data to explore the link between levels of these molecules and signs of complications in people with diabetes. Overall, this information will allow us to identify: 1) promising markers that can be measured in the blood to identify signs of diabetes complications; and 2) potential new drug targets to slow the progression of complications in people with diabetes.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 13088 | The diabetic myocardial transcriptome reveals Erbb3 and Hspa2 as a novel biomarkers of incident heart failure | Marcella S Conning-Rowland (+14) | 2024 | Cardiovascular Research |
Enabling scientific discoveries that improve human health